Apyx Medical (APYX) to Release Quarterly Earnings on Thursday

Apyx Medical (NASDAQ:APYX) is expected to be posting its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect Apyx Medical to post earnings of ($0.06) per share for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, March 10, 2026 at 8:00 AM ET.

Apyx Medical Stock Up 4.1%

Shares of NASDAQ:APYX opened at $3.30 on Thursday. The company has a market capitalization of $126.19 million, a PE ratio of -9.17 and a beta of 1.61. The company has a current ratio of 4.44, a quick ratio of 3.61 and a debt-to-equity ratio of 5.69. Apyx Medical has a twelve month low of $0.76 and a twelve month high of $4.50. The firm has a 50 day simple moving average of $3.75 and a 200-day simple moving average of $3.27.

Institutional Trading of Apyx Medical

Several hedge funds have recently modified their holdings of the business. Millennium Management LLC purchased a new position in shares of Apyx Medical in the fourth quarter valued at $324,000. 683 Capital Management LLC purchased a new position in Apyx Medical during the 4th quarter valued at about $436,000. ExodusPoint Capital Management LP acquired a new position in Apyx Medical during the fourth quarter worth about $305,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of Apyx Medical in the fourth quarter valued at about $111,000. Finally, Nantahala Capital Management LLC grew its position in shares of Apyx Medical by 19.1% in the fourth quarter. Nantahala Capital Management LLC now owns 3,974,091 shares of the company’s stock valued at $13,909,000 after purchasing an additional 636,043 shares during the last quarter. 55.33% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on APYX. Zacks Research raised shares of Apyx Medical to a “hold” rating in a research report on Wednesday, December 17th. Roth Mkm initiated coverage on Apyx Medical in a report on Monday, December 15th. They issued a “buy” rating and a $6.00 target price for the company. Wall Street Zen raised Apyx Medical to a “hold” rating in a research report on Saturday, November 22nd. Citizens Jmp raised Apyx Medical from a “market perform” rating to an “outperform” rating and set a $8.00 price target on the stock in a research report on Wednesday, November 12th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Apyx Medical in a research note on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Apyx Medical presently has an average rating of “Moderate Buy” and an average target price of $7.00.

Apyx Medical Company Profile

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.